Monitor upcoming earnings or clinical updates, the divergence between executive selling and external investor buying may reflect profit-taking post-runup rather than fundamental concerns. Watch for follow-up trades from other insiders or Lindstrom adding to his position.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 20 $7.78entry
- T+1 · 9mo ago +8.10%α +9.11% · $8.41
- T+5 · 9mo ago +14.91%α +15.36% · $8.94
- T+20 · 8mo ago +5.14%α +11.09% · $8.18
- T+60 · 6mo ago +7.71%α +0.58% · $8.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider transactions at Ocular Therapeutix (OCUL) over the past week shows mixed activity: one significant open-market purchase by external investor Dr. Richard Lindstrom for $461K, alongside coordinated open-market sales by five insiders including four C-suite executives totaling $256K. The selling is concentrated among senior leadership, while the sole buyer is not an executive officer, suggesting divergent sentiment.
Key Financial Metrics
Key Facts
- Dr. Richard L. Lindstrom, MD, purchased 60,229 shares at $7.66 for $461,354.14 on February 20, 2026, in an open-market transaction.
- Four C-suite executives, Pravin Dugel, Peter Kaiser, Jeffrey Heier, Sanjay Nayak, and Nadia Waheed, sold shares between February 20 and February 23, 2026.
- Total insider selling volume: 31,192 shares, valued at $256,374.36 across five transactions.
- All sales were open-market transactions (Form 4 code 'S'), not forced or tax-related dispositions.
- Selling executives represent key roles in development, science, strategy, and medical affairs.
Financial Impact
Net insider selling of $256K offset by $461K external purchase; no direct financial impact to company balance sheet but potential signal on internal sentiment.
Risk Factors
- Coordinated C-suite selling could signal lack of confidence in near-term prospects, especially if not part of a pre-arranged plan.
- The purchase by Lindstrom, while notable, comes from a non-executive and may not reflect internal views on valuation or pipeline risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-OCUL-1772103655330 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers